Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Five Phase 3 Studies
Presented at ECNP 2019
Major depressive disorder (MDD) is a debilitating psychiatric illness and is a major contributor to the overall global burden of disease. Nearly one-third of patients with MDD do not respond to available antidepressants (AD) and develop treatment-resistant depression (TRD). The growing prevalence of TRD and the poor response rates to ADs4 , highlight the need for novel treatments that can provide rapid and sustained relief of depressive symptoms in patients with TRD. Esketamine (ESK), the S-enantiomer of ketamine, is an N-methyl-D-aspartate (NMDA) receptor antagonist recently approved by the US FDA as a nasal spray, along with a newly administered oral AD, for therapy of TRD.